Brian Raymer
About Brian Raymer
Brian Raymer is the Executive Director of Project Leadership and Strategy at Alkermes in Waltham, Massachusetts, with extensive experience in drug discovery and development.
Title
Brian Raymer is the Executive Director of Project Leadership and Strategy at Alkermes in Waltham, Massachusetts, United States.
Current Role at Alkermes
Brian Raymer currently serves as the Executive Director of Project Leadership and Strategy at Alkermes. In this role, he is based in Waltham, Massachusetts. His responsibilities include oversight and strategic guidance for project teams working on drug discovery and development.
Career at Alkermes
Brian Raymer has held multiple positions at Alkermes. Before becoming Executive Director, he worked as the Senior Director of Project Leadership and Strategy from 2020 to 2022 and as the Discovery Project Director from 2018 to 2020. Over these years, he has been instrumental in driving project leadership structures and advancing crucial projects, including the clinical-stage orexin 2 receptor agonist ALKS 2680.
Previous Roles and Experience
Prior to Alkermes, Brian Raymer accumulated substantial experience at Pfizer and Novartis. At Pfizer, he undertook roles as Research Project Leader and Senior Principal Scientist from 2013 to 2018, contributing to metabolic drug discovery and first-in-human studies. He also chaired a multi-site chemical biology network group. At Novartis, he held the role of Investigator III from 2004 to 2013, where he worked on projects including antibody drug conjugates and GPCR-focused research.
Education and Academic Background
Brian Raymer earned his Ph.D. in Chemistry and Chemical Biology from Harvard University, where he focused on the synthesis of Azaspiracid. He also holds a B.A. in Chemistry from St. Olaf College. His early research experience includes working as a Graduate Researcher at Harvard and as a Research Assistant/Associate at Pfizer before pursuing his doctoral studies.
Project Leadership at Pfizer and Novartis
At Pfizer, Brian Raymer led coordinated teams for metabolic drug discovery projects and chaired a chemical biology network group. His work in designing and selecting clinical candidates was pivotal. At Novartis, he led cardiovascular hit-to-lead efforts and contributed compounds to diabetes projects. His role included constructing antibody drug conjugates and bioconjugations of peptides and proteins.